|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.30|
|Forward Dividend & Yield||1.11 (3.95%)|
|1y Target Est||N/A|
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.
Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.
GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.
GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.
AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.
In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.
The news that five patients on Roche’s (RHHBY) hemophilia drug Hemlibra died triggered the company’s stock to decline ~2% on March 28, 2018. It also announced that it has received a favorable ruling in a Japanese court in a patent-infringement litigation with Shire (SHPG).
Roche’s (RHHBY) Ocrevus, approved by the FDA in March 2017, is targeted at the treatment of relapsing and primary progressive forms of multiple sclerosis (or MS). Ocrevus was also approved in the European Union (or EU) for these two forms of MS in January 2018. With its rising market share, Ocrevus is a highly effective treatment option for MS, offering a highly favorable risk-benefit profile as demonstrated in three Phase 3 studies of the drug.
On April 3, 2018, Roche Holding (RHHBY) announced that its drug Alecensa has been approved in Switzerland as a first-line treatment for advanced or metastatic ALK (anaplastic lymphoma kinase)-positive NSCLC (non-small cell lung cancer). The drug was previously approved in Switzerland for treating patients with advanced or metastatic ALK-positive NSCLC that worsened after treatment with Pfizer’s (PFE) anti-cancer drug crizotinib and who could not tolerate crizotinib treatment.
On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE (National Institute for Health and Care Excellence) in England for the treatment of relapsing forms of MS in adults. Ocrevus was approved by the FDA for the treatment of adult patients suffering from relapsing-remitting MS or a primary progressive form of MS, which is more difficult to treat. The drug is the only approved therapy for the primary progressive form of MS and has given stiff competition to Merck’s (MRK) market-leading MS drug Rebif. Roche offered the drug at a 25% discount to Rebif.
On April 9, 2018, Roche (RHHBY) announced that it has received approval for Tecentriq from NICE (National Institute for Health and Care Excellence) in England for the treatment of the most common form of lung cancer. Patients with advanced NSCLC (non-small cell lung cancer) who have undergone chemotherapy for the disease but still registered disease progression can now get immunotherapy through the NHS (National Health Service), which will provide coverage for Tecentriq treatment.
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Roche Holding AG (SWX:ROG) a safer option. Doing business globally, large caps tend to haveRead More...
Exelixis shares rebounded Tuesday from a 10-month low at Monday's close after regulators temporarily halted enrollment in a cancer study combining drugs from Exelixis and Roche.
In October 2017, Emergent BioSolutions (EBS) completed the acquisition of raxibacumab from GlaxoSmithKline (GSK). Raxibacumab is a fully human monoclonal antibody with approval from the FDA for treating inhalational anthrax. Raxibacumab has orphan drug designation in the US and was approved by the FDA in 2012.
Moffitt's health informatics subsidiary wants to ditch its "best-kept secret" distinction.
Wall Street giant Goldman Sachs is making a big push for your savings accounts by offering an annual percentage yield of 1.6%. Yahoo Finance’s Alexis Christoforous, Julia La Roche, and Melody Hahm discuss how the bank is able to offer such a high percentage yield.